RxDoctor Payments Data

Teodoro Mercado, MD

Cardiovascular Disease · Manati, PRNPI 1447270038

Payments from drug & device makers

$1,639in general payments, 2019–2025

Across 30 payments — averaging $54.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$528
  • Boston Scientific$248
  • Johnson & Johnson$223
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$169
  • AstraZeneca$105
  • Pfizer Pharmaceuticals LLC$100
  • plus $266 from 4 others

What the payments were for

  • Food & beverage$1,639100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.7$528
Boston Scientific2$248
Johnson & Johnson3$223
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)6$169
AstraZeneca1$105
Pfizer Pharmaceuticals LLC1$100
Amgen5$96
Chiesi USA, Inc.1$91
Boehringer Ingelheim3$58
PBG Puerto Rico LLC1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,639 in reported general payments places this provider in the 35th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$10,430
Medicare patients
31
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab92$59,466
XareltoRivaroxaban21$15,248
Doxazosin Mesylate240$3,187
Metoprolol Succinate279$2,867
Atorvastatin Calcium253$2,039
Losartan Potassium218$1,962
Fenofibrate105$1,758
Ezetimibe122$1,702
Candesartan Cilexetil21$1,597
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide94$1,210
Irbesartan54$1,082
Amlodipine Besylate170$1,007
Hydrochlorothiazide150$995
Rosuvastatin Calcium101$932
Hydralazine Hcl74$677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$223$15,24821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Manati

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →